Precision medicine in NSCLC
Read all about it..
The Colonnade Hotel, 120 Huntington Ave 02116, Boston, MA, United States
Demcizumab in First-Line NSCLC: a novel anti-Cancer Stem Cell Agent with Immune Modulatory Properties
5T4 Antibody Drug Conjugate in NSCLC
Development of IMGN289, a novel EGFR-targeting Antibody-Drug Conjugate
Morning Refreshments & Networking
Exploiting the Folate Receptor for Targeted NSCLC therapy
MET-Targeted Therapy and NSCLC
Clinical Results in NSCLC Patients treated with Pembrolizumab
Lunch & Networking
PD1 Checkpoint Therapy in Previously Treated Non-Small Cell Lung Cancer
Targeted Therapy Against Interleukin 1 Alpha in Patients with Refractory Non Small Cell Lung Cancer
Harnessing the innate immune system to increase efficacy of cancer-targeted antibodies in NSCLC
mRNA-based drug development.
T-cell redirected cytotoxicity using a unique Anti-CD3-EGFR bispecific DVD-Ig molecule currently in pre-clinical development.
DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials
Afternoon Refreshments & Networking
Targeting HSP90 in NSCLC: Oncoprotein destabilization
and trap for targeted chemo delivery
Reolysin development in NSCLC
Panel Discussion: Immuno-Oncology in NSCLC.
Overcoming resistance to tyrosine kinase inhibitors in NSCLC: Challenges, opportunities and approaches
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
beta III-tubulin as a target for ddRNAi-based therapeutics to overcome drug resistance in NSCLC
Rx/Dx Co-Development: Ground Breaking Collaboration in Developing Ficlatuzumab for NSCLC
Morning Refreshments & Networking
Update on AZD9291: A mutant-selective EGFR inhibitor for NSCLC
Blood-Based Biopsies in NSCLC—A New Approach
Evaluation of EGFR Mutations in Plasma from NSCLC Patients: Utility in Managing Patients on TKI Therapy
Positioning your Companion Diagnostic Program for Global Success
Lunch & Networking
Panel Discussion: Biomarkers and Companion Diagnostics in NSCLC
Biomarker Analysis of Circulating Tumor (ct)DNA and Circulating Tumor Cells (CTCs)
Targeting the KRAS variant as an approach to treating NSCLC
Preclinical pharmacology work on HRG as a resistance mechanism to erlotinib in NSCLC, which subsequently led to a phase I/II clinical study of MM-121 + erlotinib.
Afternoon Refreshments & Networking
VAL-083: The Old and The New. Rethinking and repositioning a first-in-class chemotherapeutic agent in the modern treatment of non-small cell lung cancer
Bromodomain inhibition in MYC deregulated malignancies